Stop the pain: Tips for increasing patient retention and decreasing missing data in analgesia clinical trials
Rho
| « Previous month | Next month » |
Bespak, one of the two contract manufacturers of Pfizer's inhaled insulin Exubera, has announced it will cut a "significant" number of jobs as sales of the once-touted blockbuster are falling short of expectations.
Cook Pharmica, Cytovance, BioStorage Technologies, PRA International, Draxis Pharma, and MDS Pharma Services have all had people on the move in the world of pharmaceutical outsourcing.
A team of US researchers have become the first to completely suppress a gene that is crucial to HIV infection, paving the way to a protective gene therapy.
Ireland has successfully established itself as a hub for the pharma and biotech industries, and the trend to invest in high value-added activities on the green isle shows no sign of slowing, according to Ireland's Industrial Development Agency (IDA).
India's Reliance Life Sciences (RLS) is planning an acquisition in Europe or in the US joining the slow infiltration of Indian firms cementing themselves in Western markets.
The worlds of biochemistry and electronics have collided after scientists successfully developed a biosensor that can measure a drug's effectiveness without killing the cells it is trying to analyse.
Aptuit Laurus, the newly formed joint venture between Aptuit and Laurus Labs in India, will focus on an expected rise in the demand for preclinical and Phase I research and development services as part of its growth plan in India.
Teva Pharmaceuticals has licensed a drug that could offer new hope for both treating and preventing allergic reactions, according to its award-winning developers.
Six months after a couple of failed Phase III trials, Nuvelo has reinstated clinical development for its blood clot dissolving drug, but it will have to go it alone after Bayer decided enough is enough and pulled out of the collaboration.
US microfluidics company CellASIC has developed a device that enables the effects of anticancer drugs to be studied in an environment that mimics a real cancerous growth.
Asterand said it is to slash 10 per cent of its total workforce in a cost-cutting strategy although it is not a knock-on effect of the recent ban on export of human samples from Russia.
A new class of diabetes drugs is showing promising clinical results, with the big players in the field all scrapping it out for a slice of the potential rewards.
India's clinical research industry took on more shape this week with the launch of the Indian version of the Association of Clinical Research Professionals (ACRP) and the government's proposed new regulations on clinical trials conducted in the country.
The latest in a series of periodic roundups of drugs that have moved from preclinical research into clinical testing via the announcement of a Phase I trial or an application for a trial to industry regulators.
Pfizer has had its first day in a Nigerian court in a legal dispute over its alleged involvement in the death of Nigerian children during a clinical trial 11 years ago.
Procter & Gamble (P&G) has announced its intention to outsource the active pharmaceutical ingredient (API) R&D and manufacturing work undertaken at one of its US factories, with resultant closure of the site and job losses.
Granules India, Dalton Pharma Services, Polymun, and CMC Biopharmaceuticals have all announced new contract manufacturing deals this week.
In this week's review of recent activity within the preclinical research services arena, news has emerged involving Gendata, Achaogen, NiKem Research and Verona Pharma.
A virtual version of the microbe that causes tuberculosis could help 'revolutionise' TB treatment by unlocking the key to how a few cells remain resistant to drugs.
A long-awaited and in some cases, long-feared, regulatory pathway for the US Food and Drug Administration (FDA) approval of follow-on biologics is now closer to fruition.
ICON Clinical Research is stepping up its efforts to bring observational clinical research to European customers.
Researchers have discovered three potential microRNA (miRNA) tumour suppressor genes using real-time PCR (polymerase chain reaction) techniques.
Roche has committed hundreds of millions of dollars to an early-phase rheumatoid arthritis drug, a move that is indicative of big pharma's increasing tendency to license earlier phase compounds.
Microtest Laboratories and Texcel Medical have teamed up to offer biopharma firms services to help them overcome the hurdles of developing "combination products" - a fast-growing market.
An unusual drug that contains a crucial boron atom can effectively treat fungal infections, and could also prove invaluable in the effort to counter antibacterial drug resistance.
INC Research said it is now able to bring the start date for its clinical trials forward by two weeks following the implementation of a company-wide process improvement strategy.
Parexel talks to Outsourcing-Pharma about Phase I trials, touching on trends and growth opportunities, future plans for India and lessons learned from Tegenero.
China's resolve to clean up corruption in its pharma industry has intensified as the former assistant to the already-condemned-to-death former drug chief has now been charged.
A number of outsourcing misconceptions are luring companies into viewing offshoring as an easy process, new research reveals.
Genzyme has put pen to paper on a licensing deal for Ceregene's Parkinson's drug, as a rival gene therapy for the same disease shows promise in initial clinical trials.
Thermo Fisher Scientific has opened a new RNAi Discovery and Therapeutics Services Laboratory to help pharmaceutical companies in their quest for new drugs.
The contract manufacturing business that Cardinal Health sold earlier this year has just been launched as an independent operating company rebranded as Catalent Pharma Solutions.
Finnish CRO Technical Research Center (VTT) has spun-off Zora Biosciences, which becomes the only company in the Nordic region to provide metabolomics services to pharma companies - a market with high potential.
At a time when single-use manufacturing equipment is riding on a surge of popularity, in-PharmaTechnologist.com talks to Vijay Singh of GE Healthcare's newly acquired Wave Biotech unit about the impact disposables will have on the future of personalised medicines.
The latest in a series of periodic roundups of drugs that have moved from preclinical research into clinical testing via the announcement of a Phase I trial or an application for a trial to industry regulators.
Scientists have developed a faster means of searching non-gene DNA for mutations that cause disease, paving the way for faster and cheaper drug development.
Despite a lift of the ban on biological sample transportation out of Russia, the country's clinical research industry is still in the dark on the new rules to control export of such materials.
US contract research organisation (CRO) Parexel has just announced the establishment of its first operation in India.
Patheon is teaming up with formulation development services firm Senopsys to offer pharma companies combined services to test and improve drug flavour.
European and US regulatory bodies have revamped their relationship to ease administrative burdens and improve communication, as well as implementing new measures directed specifically at paediatric drug products.
A team of Canadian scientists have identified which genes help decide a stem cell's fate; a discovery that one day could lead to drugs that invoke their regenerative power.
Farfield Scientific has teamed up with Monash University, Australia to create biosensor chips that will enable researchers to unravel how membrane proteins function and interact with drug molecules.
Experts from around the world have gathered this week to discuss the best emerging therapies for a number of neurological disorders such as multiple sclerosis and stroke.
Patient registries are becoming increasingly popular as their value is now being recognised, according to an industry expert.
In the inevitable reshuffle that comes after a major acquisition, Bayer's healthcare division has today announced plans to cut 30 per cent of its drug pipeline.
Teva Pharmaceuticals has licensed some protein kinase B technology, including preclinical drug candidates, adding to the buzz around this up-and-coming cancer target.
US firm Aptuit has announced it will invest $100m (€75m) in India-based Laurus Labs to form a new joint venture - just a few months after splurging a similar amount to expand its capabilities.
Diamyd Medical will continue with a clinical trial of its gene therapy designed to protect insulin-producing cells in diabetes patients, despite major errors invalidating the study.
Dutch ingredients firm DSM has announced plans to carve out its anti-infectives business and boost its presence in Asian markets following a review of the active ingredient unit.
UK-based Synexus was optimistic last week when it announced its preliminary financial results for the year, despite a plummeting operating profit.
Just over a week after Roche was forced to initiate a Europe-wide recall of HIV drug Viracept (nelfinavir), in-PharmaTechnologist.com considers the contamination case and the pharmaceutical processes blamed for the incident.
In a round-up of motley pharmaceutical services contracts, Outsourcing-Pharma takes a look at recent news involving Movianto, PDI, inVentiv Health and Exel.
GlaxoSmithKline's (GSK) new drug to treat a rare form of bleeding disorder has shown good results in trials so far, but while experts remain mystified as to why it works, a true cure will remain elusive.
Nicholas Piramal India (NPIL) has opened its second clinical research facility and is eyeing the growing area of biopharmaceutical testing.
The latest in a series of periodic roundups of drugs that have moved from preclinical research into clinical testing via the announcement of a Phase I trial or an application for a trial to industry regulators.
The loss of a significant contract has left West Pharmaceutical Services wielding the axe at one of its UK facilities.
The former director of the country's State Food and Drug Administration (SFDA) has lodged an appeal against the death penalty slapped on him after a corruption conviction.
Pfizer is to plough $300m (€226m) into South Korean research and development over the next five years, while it's CEO is planning to visit North Korea tomorrow.
Lonza is building a new plant in its home country to become the only contract manufacturer with large-scale capacity for making highly potent active pharmaceutical ingredients (APIs).
A drug that provides the brain with an alternative energy source to glucose is helping to roll back the symptoms of Alzheimer's disease.
Indian private equity firm ICICI Venture has taken over the ownership of US site management organisation (SMO) Radiant Research as it seeks to evolve.
German researchers have developed a microfluidic device that greatly increases the efficiency of measuring the melting temperature of DNA double strands.
Researchers have used a protein lysate array to profile and classify multiple components of aberrant cell signalling pathways in 90 cancer cell lines.
BioFocus DPI has released a new informatics system that can combine chemical and biological data from various sources to optimise protein kinase inhibitor candidate selection.
Asterand has announced a restructure and changes to its operational model in a bid to grasp hold of profitability.
Pharmaceutical companies are actually set to benefit from reduced testing requirements now that the new European chemicals regulation is in place, however, some bulk manufacturers and ingredients suppliers could face increased burdens.
GlaxoSmithKline (GSK) outlined more details on the mechanism of its anticancer drug ofatumumab - an antibody that was the subject of the biggest ever pharma licensing deal.
After dismal second quarter results Patheon is stepping up its resolve for 'damage control' and indicated that further cutbacks at its problematic Puerto Rico plant are imminent.
Diverse manufacturer 3M has agreed to sell off another chunk of its pharmaceuticals business, fourteen months after it decided to give up on the 'very competitive' industry.
Agilent has launched a new tool that removes the 14 most abundant proteins found in blood plasma and serum to speed up the discovery and identification of low-abundance proteins and biomarkers.
This year's American Society for Clinical Oncology (ASCO) conference is over and as 45,000 scientists head home, DrugResearcher.com looks at some of the most innovative drugs that were on show.
The fallout from a US Food and Drug Administration (FDA) probe continues to haunt MDS Pharma, dragging it into the red again during the second quarter.
Histological evidence of tumour destruction has confirmed the promise of Epeius Biotechnologies' Rexin-G as an effective targeted gene therapy platform for metastatic cancer.
China has announced a crackdown on its drug safety regulations in an attempt to remedy its international reputation as a producer of unsafe and counterfeit drugs.
A drug that is popularly used to treat high blood pressure and stroke could also be used to rejuvenate dopamine neurons in the brain, according to US scientists.
Just as the clinical trials sector in Russia is starting to take off, the industry has been dealt a severe blow with the sudden and indefinite banning of biological sample exports.
Further evidence has emerged claiming that clinical trials are more likely to report positive results when funded by drug companies.
Amsterdam Molecular Therapeutics (AMT) lead candidate AMT 011, a Lipoprotein Lipase (LPL) Deficiency treatment has received Orphan Drug Designation from the US Food and Drug Administration (FDA).
Outsourcing-Pharma tracks the latest eClinical movements, featuring ClinPhone, Phase Forward, etrials and DecisionView.
The apparent inability of current analytical techniques to fully characterise complex biological drugs still stands in the way of easy approval pathways for 'biogenerics' or copies of off-patent brand name biologics.
UK's Intertek Pharmaceutical Services is expanding the range of its offerings with the acquisition of QTI, a US contract analytical laboratory.
A molecule that links spontaneous physical activity such as fidgeting and food intake could be a promising new target for drugs to control diet-induced obesity, researchers from Europe and the US suggest.
Abbott is the latest pharmaceutical company to scoop up Dowpharma's exclusive protein-producing technology.
A new drug from Merck KGaA could be the first in a new type of anticancer therapy that works by starving the tumour of its blood supply.
Japanese researchers have developed a way to increase protein sequence coverage by removing the need for organic matrices that can mask low weight analytes during MALDI-MS experiments.
Two Chinese contract research organisations (CROs) have announced they will merge - a first in China's CRO industry.
The number of clinical trial registries that drug companies and researchers can use if they want to have their results later published in prominent medical journals has been increased. Meanwhile, as of July next year, Phase I trials will also have to comply with the registration requirements.
Oxigene's potentially first-in-class cancer drug is showing promising clinical results and could rival a drug Novartis' recently spent nearly a billion dollars on.
The seventeenth in a series of periodic roundups of drugs that have moved from preclinical research into clinical testing via the announcement of a Phase I trial or an application for a trial to industry regulators.
Sponsors need to ensure they are managing the risk involved in clinical outsourcing, particularly when dealing with multiple contractors.
Morphotek, CMC Biopharmaceuticals, Cobra Biomanufacturing, and Fraunhofer have all announced new contract manufacturing deals this week, while Jubilant Organosys completed its US buyout.
DeltaDOT has been given a government grant to commercially develop a new tool to allow researchers to reduce dramatically the time it takes to weed out unsuitable drug candidates.
The pharmaceutical and healthcare industries will help to push trade between India and the United Kingdom up by 60 per cent within three years, claims a soon-to-be released report.
Kendle received good news after being rated top contract research organisation (CRO) in the US by a survey of more 500 clinical investigative sites.
In a bid to push manufacturers to reduce their greenhouse gas emissions, the UK government last week unveiled a proposal that could pave the way for "carbon footprint" labels on products.
Phase 0 studies have a great potential in selecting drug candidates early in the drug development but the pharma industry will stay sceptical until more research has been done, said Prof. Colin Garner, CEO of microdosing service firm Xceleron.
Newly-formed Brane Discovery has licensed a Parkinson's research programme to become the third company in three years to own the potentially first-in-class drug candidates.
A new approach to Phase I clinical trials could revolutionise drug development, enabling innovative drugs to get to market faster and cheaper.
Analysing the images from protein separation experiments, such as 2D gel electrophoresis (2DGE), is not only time consuming but can often miss 'hits' and give false positives. But it doesn't have to be that way, according to Swedish company Ludesi.
Wyeth has presented more clinical data for its first-in-class cancer drug, which was approved for use in the US last week.
The European Commission has released figures showing that there has been a dramatic and concerning increase in pharmaceutical counterfeiting, with seizures in Europe hitting an all time high of over 2.5m items.
Veeda Clinical Research, an Anglo-Indian contract research organisation (CRO) formed two years ago, said it will soon enter the US market with a new acquisition - the fourth since the company's creation.
British drug maker AstraZeneca has awarded UK-based NYK Logistics a two and a half year contract for the distribution of its drugs throughout Europe, worth £6m (€8.9m).
Japanese researchers have developed a high throughput method for screening the activity of beta-amyloid protein aggregation inhibitors that should speed up the discovery of new Alzheimer's therapies.
The world's biggest cancer conference kicked off this weekend with drug companies from around the world keen to showcase their new therapies.
In a groundbreaking decision, Janssen-Cilag has offered to give the UK government their money back if its expensive new bone cancer treatment does not work on patients.
| « Previous month | Next month » |